Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

211
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
211
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

318
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
318
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

174
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
174
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

1.2K
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zwei neue Verfahren der Atemstrommessung.

Biomedizinische Technik. Biomedical engineering·2011
Same author

Externally portable and implantable devices for continuous delivery of analgetics.

Acta neurochirurgica. Supplementum·1987
Same author

One year continuous run with a totally implantable insulin infusion pump in a human diabetic.

Transactions - American Society for Artificial Internal Organs·1983
Same author

Development of remotely controlled implantable devices for programmed insulin infusion.

Life support systems : the journal of the European Society for Artificial Organs·1983
Same author

Clinical experience in human diabetics with portable and implantable insulin minipumps.

Life support systems : the journal of the European Society for Artificial Organs·1983
Same author

Total implantation of a remotely controlled insulin minipump in a human insulin-dependent diabetic.

Artificial organs·1982

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Direct Infusion Device for Molecule Delivery in Plants
08:52

Author Spotlight: Direct Infusion Device for Molecule Delivery in Plants

Published on: June 2, 2023

3.8K

Drug delivery by program or sensor controlled infusion devices.

M Franetzki1

  • 1Siemens AG, Medizinische Technik, Postfach 3260, D-8520, Erlangen.

Pharmaceutical Research
|November 27, 2013
PubMed
Summary
This summary is machine-generated.

Controlled drug delivery systems offer disease treatment benefits. However, variable rate implantable pumps for conditions like diabetes face challenges due to insulin incompatibility and lack of long-term glucose sensors.

More Related Videos

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

15.1K
High Speed Droplet-based Delivery System for Passive Pumping in Microfluidic Devices
10:22

High Speed Droplet-based Delivery System for Passive Pumping in Microfluidic Devices

Published on: September 2, 2009

13.0K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Direct Infusion Device for Molecule Delivery in Plants
08:52

Author Spotlight: Direct Infusion Device for Molecule Delivery in Plants

Published on: June 2, 2023

3.8K
Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

15.1K
High Speed Droplet-based Delivery System for Passive Pumping in Microfluidic Devices
10:22

High Speed Droplet-based Delivery System for Passive Pumping in Microfluidic Devices

Published on: September 2, 2009

13.0K

Area of Science:

  • Biomedical Engineering
  • Drug Delivery Systems
  • Medical Device Technology

Background:

  • Controlled drug administration is crucial for managing various diseases.
  • Externally portable and fixed-rate implantable drug delivery devices are increasingly adopted.
  • Variable-rate implantable pumps offer therapeutic advantages but face significant technical hurdles.

Purpose of the Study:

  • To review the current state and challenges of controlled drug delivery devices.
  • To highlight the specific issues hindering the widespread use of variable-rate implantable pumps for diabetes management.
  • To discuss the future potential of closed-loop feedback-controlled implantable systems.

Main Methods:

  • Literature review of existing drug delivery technologies.
  • Analysis of material compatibility issues in implantable pumps.
  • Assessment of sensor technology limitations for closed-loop systems.

Main Results:

  • Insulin incompatibility with pump materials at body temperature is a major obstacle for diabetes therapy.
  • The absence of reliable, long-term implantable glucose sensors prevents the development of ideal feedback-controlled systems.
  • Ongoing clinical trials are evaluating the cost-benefit-risk profiles of current and emerging drug delivery applications.

Conclusions:

  • Advancements in materials science are needed to overcome insulin pump incompatibility.
  • Development of robust long-term glucose sensors is critical for realizing advanced implantable drug delivery systems.
  • Further clinical evaluation is essential to determine the ultimate clinical utility and economic viability of these technologies.